IN2012DN01984A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01984A IN2012DN01984A IN1984DEN2012A IN2012DN01984A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A IN 1984DEN2012 A IN1984DEN2012 A IN 1984DEN2012A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A
- Authority
- IN
- India
- Prior art keywords
- tfpi
- aptamers
- bind
- disorders
- nostics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The invention relates gener¬ally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diag¬nostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI ap¬tamers may be used before, during and/or af¬ter medical procedures to reduce complica¬tions or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23493909P | 2009-08-18 | 2009-08-18 | |
US35337410P | 2010-06-10 | 2010-06-10 | |
US36636210P | 2010-07-21 | 2010-07-21 | |
US36776610P | 2010-07-26 | 2010-07-26 | |
PCT/US2010/045797 WO2011022427A1 (en) | 2009-08-18 | 2010-08-17 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01984A true IN2012DN01984A (en) | 2015-07-24 |
Family
ID=43607310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1984DEN2012 IN2012DN01984A (en) | 2009-08-18 | 2010-08-17 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8252913B2 (en) |
EP (1) | EP2467167B1 (en) |
JP (1) | JP2013502218A (en) |
KR (1) | KR20120061086A (en) |
CN (1) | CN102869385A (en) |
AU (1) | AU2010284329B2 (en) |
BR (1) | BR112012003806A2 (en) |
CA (1) | CA2770762A1 (en) |
CO (1) | CO6531414A2 (en) |
ES (1) | ES2655589T3 (en) |
IL (1) | IL218048A0 (en) |
IN (1) | IN2012DN01984A (en) |
MX (1) | MX2012002133A (en) |
NZ (1) | NZ598557A (en) |
RU (1) | RU2012110221A (en) |
SG (1) | SG178408A1 (en) |
WO (1) | WO2011022427A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
EP3260466A1 (en) | 2008-12-22 | 2017-12-27 | Novo Nordisk A/S | Anti-tfpi antibodies |
JP6002691B2 (en) * | 2011-02-11 | 2016-10-05 | バクスアルタ ゲーエムベーハー | Aptamers for tissue factor pathway inhibitors and their use as therapeutic agents for bleeding disorders |
KR20140066977A (en) * | 2011-06-08 | 2014-06-03 | 미에드지나로도위 인스티투트 바이오로지 모레쿠라네지 아이 코모르코웨즈 | Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins |
EP2827910A2 (en) * | 2012-03-22 | 2015-01-28 | Baxter International Inc | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
DE102012020496A1 (en) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample |
JP6502930B2 (en) * | 2013-06-21 | 2019-04-17 | イミジン, インコーポレイテッド | Blood analysis |
EP3022228B1 (en) | 2013-07-19 | 2019-02-27 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
WO2015035305A1 (en) * | 2013-09-09 | 2015-03-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
CA2944909A1 (en) * | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
EP4378487A2 (en) * | 2015-06-23 | 2024-06-05 | The Children's Hospital of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
WO2017062536A2 (en) * | 2015-10-06 | 2017-04-13 | Kieu Hoang | A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv |
AU2016364431B2 (en) | 2015-12-04 | 2020-08-27 | Zenyaku Kogyo Co., Ltd. | Anti-IL-17 aptamer having improved retention in blood |
CN112442127A (en) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | Monoclonal antibodies against TFPI |
CN115792231B (en) * | 2022-11-04 | 2023-07-25 | 中拓生物有限公司 | DNase I biosensor based on thrombin aptamer-regulated enzyme cascade reaction |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5981471A (en) | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
EP1039935A4 (en) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
CA2302805A1 (en) | 1997-09-05 | 1999-03-11 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
EP2045337B1 (en) | 1998-11-09 | 2011-08-24 | Eiken Kagaku Kabushiki Kaisha | Process for synthesizing nucleic acid |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
WO2003102212A2 (en) * | 2002-05-31 | 2003-12-11 | Regents Of The University Of Minnesota | In vitro evaluation of nucleic acid ligands |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
EP1919499A2 (en) * | 2005-07-29 | 2008-05-14 | Universiteit van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
-
2010
- 2010-08-17 NZ NZ598557A patent/NZ598557A/en unknown
- 2010-08-17 EP EP10810508.1A patent/EP2467167B1/en active Active
- 2010-08-17 WO PCT/US2010/045797 patent/WO2011022427A1/en active Application Filing
- 2010-08-17 KR KR1020127007005A patent/KR20120061086A/en not_active Application Discontinuation
- 2010-08-17 CN CN2010800457286A patent/CN102869385A/en active Pending
- 2010-08-17 AU AU2010284329A patent/AU2010284329B2/en active Active
- 2010-08-17 IN IN1984DEN2012 patent/IN2012DN01984A/en unknown
- 2010-08-17 SG SG2012010245A patent/SG178408A1/en unknown
- 2010-08-17 JP JP2012525649A patent/JP2013502218A/en not_active Withdrawn
- 2010-08-17 CA CA2770762A patent/CA2770762A1/en not_active Abandoned
- 2010-08-17 US US12/858,369 patent/US8252913B2/en active Active
- 2010-08-17 ES ES10810508.1T patent/ES2655589T3/en active Active
- 2010-08-17 BR BR112012003806A patent/BR112012003806A2/en not_active Application Discontinuation
- 2010-08-17 MX MX2012002133A patent/MX2012002133A/en active IP Right Grant
- 2010-08-17 RU RU2012110221/10A patent/RU2012110221A/en unknown
-
2012
- 2012-02-12 IL IL218048A patent/IL218048A0/en unknown
- 2012-03-16 CO CO12046249A patent/CO6531414A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ598557A (en) | 2013-08-30 |
KR20120061086A (en) | 2012-06-12 |
EP2467167A4 (en) | 2013-12-25 |
CA2770762A1 (en) | 2011-02-24 |
SG178408A1 (en) | 2012-03-29 |
US20110098345A1 (en) | 2011-04-28 |
AU2010284329B2 (en) | 2015-04-16 |
ES2655589T3 (en) | 2018-02-20 |
BR112012003806A2 (en) | 2016-11-16 |
WO2011022427A1 (en) | 2011-02-24 |
US8252913B2 (en) | 2012-08-28 |
RU2012110221A (en) | 2013-09-27 |
AU2010284329A1 (en) | 2012-03-29 |
EP2467167B1 (en) | 2017-08-16 |
JP2013502218A (en) | 2013-01-24 |
CN102869385A (en) | 2013-01-09 |
IL218048A0 (en) | 2012-04-30 |
MX2012002133A (en) | 2013-02-15 |
EP2467167A1 (en) | 2012-06-27 |
CO6531414A2 (en) | 2012-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01984A (en) | ||
MX2012011771A (en) | Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders. | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MX2021007268A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof. | |
WO2012174487A8 (en) | Bromodomain inhibitors and uses thereof | |
WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
WO2012088290A3 (en) | Tri-variable domain binding proteins and uses thereof | |
WO2012075383A3 (en) | Bromodomain inhibitors and uses thereof | |
PH12016500182A1 (en) | Anti-activin a antibodies and uses thereof | |
WO2013151736A3 (en) | In vivo production of proteins | |
MY169987A (en) | Selective pi3k delta inhibitors | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
WO2012138487A3 (en) | Oligonucleotide modulation of splicing | |
WO2011060049A3 (en) | Spiro-oxindole mdm2 antagonists | |
WO2014028493A3 (en) | Exosomes and micro-ribonucleic acids for tissue regeneration | |
WO2013151666A3 (en) | Modified polynucleotides for the production of biologics and proteins associated with human disease | |
EP2590671A4 (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2012065022A3 (en) | Spiro-oxindole mdm2 antagonists | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
MX2013012053A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
SG10201804817TA (en) | Delayed release compositions of linaclotide | |
WO2010083207A3 (en) | Protein kinase c inhibitors and uses thereof | |
MX347734B (en) | S100a4 antibodies and therapeutic uses thereof. | |
WO2014159669A3 (en) | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions |